The CMBL Knockout Raji Polyclonal Cells product provides a ready-to-use population of suspension-adapted human B lymphocytes carrying a targeted disruption of the CMBL gene introduced by CRISPR/Cas9 genome editing. This polyclonal knockout model abolishes endogenous carboxymethylenebutenolide hydrolase (CMBL) expression without clonal selection, enabling functional studies in a genetically heterogeneous cell pool that retains key characteristics of the host Raji line. The cells are supplied as a viable cryopreserved suspension culture suitable for immediate expansion and downstream biochemical or pharmacological assays.
Raji cells are an Epstein-Barr virus (EBV)-positive B lymphocyte line originally derived from a patient with Burkitt??s lymphoma. They grow in suspension with lymphoblastoid morphology and are widely employed as a model system for B cell receptor signaling, antigen presentation, and antibody production. The EBV-transformed status confers robust proliferation and ease of genetic manipulation, while the Burkitt??s lymphoma origin provides a relevant background for investigating B-cell malignancies and chemotherapeutic responses. Their constitutive expression of key drug-metabolizing enzymes and transporters makes them a valuable host for evaluating intracellular prodrug activation and detoxification pathways.
CMBL encodes a serine hydrolase that cleaves carboxymethylenebutenolide rings present in certain ester prodrugs and xenobiotics. It functions downstream of constitutive expression and potential xenobiotic-induced regulatory signals to generate active metabolites, such as the thiolactone form of the antiplatelet agent prasugrel, or hydrolysis products that modulate drug activity. CMBL operates within a broader esterase network alongside carboxylesterases CES1 and CES2, which hydrolyze diverse ester substrates, and cytochrome P450 enzymes including CYP3A4 and CYP2B6 that mediate oxidative biotransformation. Efflux transporter ABCB1 further influences intracellular accumulation of metabolites. The enzyme??s activity is regulated by substrate availability and possibly by xenobiotic-sensing transcription factors, though direct protein cofactors are not identified. Knockout of CMBL disrupts this catalytic step, altering metabolic flux through these interconnected pathways.
Elimination of CMBL in the Raji B-cell background creates a powerful tool for dissecting the contribution of this specific hydrolase to prodrug activation and drug resistance in a lymphoma-relevant context. Because Raji cells express numerous drug-processing enzymes, the knockout model allows researchers to attribute changes in cellular sensitivity specifically to loss of CMBL function. This is particularly relevant for studying variable responses to antiplatelet prodrugs and the toxicity of chemotherapeutics that utilize similar activation mechanisms. Combined with the EBV-positive state and high proliferative capacity, these polyclonal knockout cells enable reproducible screening of ester prodrug libraries and investigation of compensatory upregulation within the serine hydrolase family.
The product is suitable for a wide range of applications, including in vitro metabolism studies using LC-MS to track substrate-to-metabolite conversion, cell viability assays with prasugrel or other ester prodrugs, and fluorogenic CMBL activity measurements to validate loss of function. It can be employed in high-throughput screening of hydrolase inhibitors, RT-qPCR profiling of related metabolic genes, and apoptosis analysis by flow cytometry to assess drug-induced cytotoxicity. Researchers may also combine this model with overexpression or pharmacological modulation of pathway components such as CES1, CYP3A4, or ABCB1 to reconstruct metabolic networks. For additional information or technical support, please contact Ascent Research.
